UC Berkeley Study Finds Compound TOFA Promotes Fat Loss in Mice

Industry Pulse News Desk · 2026-08-31

A study shows the 1970s metabolic compound TOFA reduced body fat in obese mice while maintaining lean muscle mass.

Researchers at the University of California, Berkeley, have discovered that a compound originally developed in the 1970s significantly increases energy expenditure and targets fat loss in obese mice. The substance, known as TOFA, allowed the subjects to shed fat without experiencing the muscle degradation often associated with weight loss treatments.

According to the published findings, TOFA inhibits a key enzyme involved in fatty acid synthesis, effectively shifting metabolic processes toward burning existing fat stores. During the animal trials, obese mice treated with the compound demonstrated elevated energy usage while maintaining their overall lean body mass.

In addition to acute weight loss, the research team observed sustained benefits following the cessation of treatment. Laboratory mice that received TOFA maintained lower body weights for an extended period after the dosing regimen ended, compared to control groups that rapidly regained lost fat mass.

Preserving muscle mass remains a critical challenge in therapeutic weight management, as standard caloric restriction and existing pharmaceuticals frequently lead to the concurrent loss of lean muscle tissue. By selectively targeting fat metabolic pathways, TOFA presents a potential blueprint for future metabolic drug development.

While the results in animal models demonstrate a clear mechanism for targeted fat loss, further studies are required to determine whether TOFA or similar derivatives can be safely and effectively administered to humans. The research team noted that clinical safety trials remain necessary before any potential therapeutic applications can be pursued.